Sean Mcdonald Email & Phone Number

Pittsburgh, Pa, Us

Ocugenix is a clinical-stage therapeutics company focused on diseases of the eye. Our first clinical indication will be wet macular degeneration, the number one cause of blindness in people over 50. This is currently a $9 billion market. Our first compound is a peptide with both anti-angiogenic and anti-fibrotic activity. The FDA recently granted the company an IND and is beginning human trials in the fall of 2023. Ocugenix’s compound, Ocupep, is one of only five clinical programs in this indication and the only one with a mechanism of action other than anti-VEGF. Our second indication is Dry-Eye disease, a $5 billion market opportunity the company plans to start its clinical program in early 2024. This new compound is the only program in the Dry Eye indication that has shown the ability to regrow the stem cells and goblet cells that are critical to the eye's health and the normal production of tears.

Pittsburgh, Pa, Us

Board Member of Developmental Stage Biotech company developing proprietary diagnostics for the treatment of Breast Cancer. Company is using machine learning and genomic technologies to identify the best predictors of response to therapy.

Mountain View, California, Us

Imprimed is a personalized medicine company developing proprietary diagnostics for the Veterinary market place. Company is based on proprietary technology developed out of the BioMedical Engineering group at Stanford. Company is also in the midst of human clinical trials in Korea for a diagnostic to treat lymphoma and leukemia.

Greenwich, Ct, Us

Turnaround CEO of a venture-backed SAAS businesses in the online marketing space. Responsibility was to restructure several venture capital backed companies to achieve positive cash flow positive and restructure the business model.

Pittsburgh, Pennsylvania, Us

Aethon is a Healthcare technology business that provides hospitals and healthcare institutions with automated technology that manages their logistics, materials, pharmacy and dietary functions within the healthcare setting. The company has leveraged its technology platform to serve industrial logistics segment as well.Company was acquired by Singapore based ST Engineering, a $6.8 billion multi-national, in August of 2017.

Us

Adams Capital Management, Inc. (ACM) is a national venture capital firm specializing in early-stage applied technology investments. ACM's portfolio companies are lead by innovative technology entrepreneurs and experienced management teams who are defining and dominating product categories. ACM's Investment Team leverages its collective operations and industry expertise in the information technology, networking infrastructure and semiconductor industries to help the portfolio companies commercialize their technology vision into self-sustaining, market-leading, companies.

Pittsburgh, Pennsylvania, Us

Precision Therapeutics is dedicated to the individualization of cancer treatment and the development and delivery of treatment support tools and services that assist physicians and benefit cancer patients.Developed a proprietary biological phenotypic and genomic product that would predict a patient's sensitivity to a variety of cancer treatments. Executed 6 year prospective clinical study demonstrating an 18 month survival advantage from the assay. Built and developed clinical, scientific, direct sales and reimbursement team to execute on plan. Built to revenues of $40 million per year.Negotiated multiple acquisitions to extend the genomic product line. Negotiated several large distribution deals with Fortune 100 companies to fill out the product portfolio.Raised over $100 million of Venture funding including first tier venture funds and private equity. Extensive experience with multiple forms of financing including debt and equity instruments.Took the company through the IPO process sponsored by JP Morgan and Piper Jaffray. Was one month from being deemed "effective" by the SEC when Lehman Brothers failed. Explored multiple financing alternatives including SPAC financing.Company was sold to Private Equity.

Amsterdam, Noord-Holland, Nl

Respironics, Inc. is the world leader in the design, development, manufacturing, and marketing of medical devices used primarily in homes, hospitals, alternative care facilities, and emergency medical settings for the treatment of patients suffering from sleep and respiratory disorders. The company was acquired in March of 2008 by Philips Holding USA Inc. for $5.1 Billion.Responsibilities included: Member of the Audit Committee, Chairman of the Compensation Committee

Irving, Texas, Us

Group President of the Automation Group. Responsible for Technologies serving the hospital, retail pharmacy and mail-order pharmacy sectors. Reported to the Chief Executive Officer. Managed 5 Division Presidents.

Automated Healthcare developed and marketed the first systems that automated the dispensing and administration of medication in hospital pharmacies. The system employed patented robotic technology to dramatically reduce medication errors and decrease the cost of managing the pharmacy function. The system has been successfully deployed in several hundred hospital pharmacies across the country and dispenses a half a billion prescriptions annually error-free.System was named by Forbes Magazine as "Five Robots That Will Change Your Life" www.forbes.com/2004/02/17/cx_ah_mh_robotslide_3.htmlThe company was acquired by McKesson for $65 million.

Courses Towards A Mba

Msc, Computer Science Engineering

Bs, Chemical Engineering

Education record